Preliminary results of safety and efficacy of the interleukin 1 receptor antagonist anakinra in patients with severe lupus arthritis

Annals of the Rheumatic Diseases
B OstendorfM Schneider

Abstract

Joint involvement occurs in most patients with systemic lupus erythematosus (SLE), and severe lupus arthritis is often refractory to conventional treatments. Anakinra is used in the treatment of rheumatoid arthritis, but its therapeutic potential has not been proved in patients with SLE. To determine the safety/tolerability and efficacy of anakinra in patients with SLE with leading joint involvement. In patients with SLE with active polyarthritis and no other uncontrolled systemic/organ manifestations, 100 mg/day anakinra was self administered subcutaneously for 3 months. Disease activity was assessed by VAS, number of swollen/tender joints, ECLAM score, and serological and immunological measures. Four patients with SLE were studied; anakinra was safe in all four patients and no drug related serious adverse events occurred. A subjective benefit was seen in all patients and a trend towards better activity measures after 4 weeks. After an initial response, one patient left the study because of an arthritic flare after 6 weeks. In this study anakinra was apparently safe and well tolerated and led to clinical and serological improvement. Anakinra might be an interesting alternative in individual patients with lupus arthritis not re...Continue Reading

Citations

Aug 13, 2010·Zeitschrift für Rheumatologie·I Kötter, G Horneff
Sep 17, 2009·Zeitschrift für Rheumatologie·B MangerUNKNOWN German Society of Rheumatology
Nov 7, 2013·Zeitschrift für Rheumatologie·I Kötter, J C Henes
May 5, 2010·Nature Reviews. Rheumatology·Lars Rönnblom, Keith B Elkon
Aug 1, 2007·The Journal of Experimental Medicine·Joanna R GroomFabienne Mackay
Jul 27, 2011·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Laurie S DavisChandra Mohan
Apr 5, 2008·Current Opinion in Rheumatology·Axel Finckh, Cem Gabay
Nov 21, 2007·Annals of the Rheumatic Diseases·D E FurstM E Weinblatt
Nov 4, 2009·Mediators of Inflammation·Manfred Kunz, Saleh M Ibrahim
Apr 14, 2012·International Journal of Rheumatology·Mariana PostalSimone Appenzeller
Jul 20, 2010·Immunotherapy·Antonio La Cava
Dec 25, 2013·Annual Review of Immunology·Nunzio Bottini, Erik J Peterson
Jan 8, 2013·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Martin AringerMin Ae Lee-Kirsch
Jun 8, 2014·La Revue de médecine interne·Y JamillouxT Henry
Apr 25, 2012·Cellular and Molecular Life Sciences : CMLS·Kristina LudigsGreta Guarda
Dec 17, 2014·Expert Review of Clinical Immunology·Alessia LeoneMunther Khamashta
Dec 9, 2014·Expert Opinion on Drug Safety·Martin Aringer, Josef S Smolen
Dec 3, 2014·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Christian J MaineLinda A Sherman
Jun 30, 2015·Translational Research : the Journal of Laboratory and Clinical Medicine·Sara S McCoyJ Michelle Kahlenberg
Jul 28, 2012·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Tiffany N CazaAndras Perl
Jan 23, 2016·Expert Review of Clinical Pharmacology·Anna Sophie Klaeschen, Joerg Wenzel
Dec 18, 2010·Trends in Molecular Medicine·Patrick J ShawThirumala-Devi Kanneganti
Jan 5, 2010·Joint, Bone, Spine : Revue Du Rhumatisme·Anna Moltó, Alejandro Olivé
Mar 21, 2007·Joint, Bone, Spine : Revue Du Rhumatisme·Thierry LequerréXavier le Loët
Apr 21, 2006·Immunological Reviews·Emily C BaechlerTimothy W Behrens
Jan 23, 2014·Arthritis & Rheumatology·Westley H Reeves
Oct 3, 2006·Current Opinion in Immunology·Lucienne Chatenoud
Sep 19, 2006·Best Practice & Research. Clinical Rheumatology·Danielle BurgerCem Gabay
Apr 2, 2016·Zeitschrift für Rheumatologie·S WinklerA Rösen-Wolff
Sep 10, 2005·Best Practice & Research. Clinical Rheumatology·Jennifer H Anolik, Martin Aringer
Nov 24, 2011·Clinical & Developmental Immunology·Yuya Takakubo, Yrjö T Konttinen
Apr 22, 2015·Seminars in Immunopathology·Pedro H V SaavedraMohamed Lamkanfi
Dec 4, 2012·Clinical Immunology : the Official Journal of the Clinical Immunology Society·Daniel N ClarkBrian D Poole
Jun 3, 2016·Journal of Translational Medicine·Hui ZhangNiansheng Yang
Jun 17, 2016·Nature Reviews. Disease Primers·Arvind KaulGraham Hughes
Jan 25, 2017·Expert Opinion on Biological Therapy·Juan ChenXiaoming Liu
Apr 6, 2005·Clinical and Experimental Immunology·F Goldblatt, D A Isenberg
May 14, 2011·Journal of the American Society of Nephrology : JASN·Hans-Joachim Anders, Daniel A Muruve
May 1, 2006·Expert Review of Clinical Immunology·Roy Fleischmann
Jun 10, 2009·Expert Opinion on Pharmacotherapy·Lisa Francis, Andras Perl
Jan 19, 2020·The Journal of Immunology : Official Journal of the American Association of Immunologists·Lihua ShiKathleen E Sullivan

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.